Lecanemab in Early Alzheimer’s Disease

To the Editor: In the phase 3 Clarity AD trial by van Dyck et al. (Jan. 5 issue), 1 the primary end point was the change from baseline to 18 months in the score on the Clinical Dementia Rating–Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating greater impairment). The min...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 17; pp. 1630 - 1632
Main Authors Zeng, Bing-Syuan, Tseng, Ping-Tao, Liang, Chih-Sung, Valenzuela, Michael J., Pascual-Leone, Alvaro, Pomara, Nunzio, Imbimbo, Bruno P., Brenman, Jay E., van Dyck, Christopher H., Sabbagh, Marwan, Cohen, Sharon
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 27.04.2023
Subjects
Alzheimer Disease
Alzheimer's disease
Biomarkers
Cerebrospinal fluid
Clinical trials
Cognitive ability
Conflicts of interest
Dementia disorders
Humans
Neurodegenerative diseases
Positron-Emission Tomography
Womens health
Taiwan
Online AccessGet full text

Cover

More Information
Summary:To the Editor: In the phase 3 Clarity AD trial by van Dyck et al. (Jan. 5 issue), 1 the primary end point was the change from baseline to 18 months in the score on the Clinical Dementia Rating–Sum of Boxes (CDR-SB; scores range from 0 to 18, with higher scores indicating greater impairment). The minimal clinically relevant change in the CDR-SB score has been estimated to be 1 to 2 points. 2 At 18 months, the CDR-SB score had increased from baseline by 1.21 points with lecanemab and by 1.66 points with placebo, for a significant between-group difference of −0.45 points. 1 . . .
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Commentary-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2301380